Illustration of amyloid plaques (orange) among brain cellsScience Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
The truth about the new class of Alzheimer’s drugs
Related Posts
Putin orders Russian army to become second largest after China’s at 1.5 million-strong
Russian army servicemen walk at an exhibition displaying armoured vehicles and equipment captured by the Russian army from Ukrainian forces in the course of Russia-Ukraine conflict, at Victory Park open-air…
Major pipeline fire outside Houston forces evacuations
Emergency responders are tackling a major pipeline fire in suburban Houston, Texas, as residents in some surrounding communities have been told to evacuate, local authorities said on Monday.The pipeline fire…